Overview

Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.
Phase:
Phase 1
Details
Lead Sponsor:
St. Luke's-Roosevelt Hospital Center
Collaborator:
Sanofi
Treatments:
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Pancreatin
Pancrelipase